Case series of COVID-19 outcomes in adult patients with inborn errors of immunity
Abstract
Background: Since the onset of the COVID-19 pandemic, a main challenge for clinicians and public health decision-makers has revolved around risk stratification in vulnerable populations, in particular individuals with inborn errors of immunity (IEI). However, available reports of the clinical course of COVID-19 in patients with IEI show wide variability, from a complete lack of symptoms to severe and complicated disease.
Objective: To present the clinical features and outcomes of SARS-CoV-2 infection in adult patients with IEI.
Methods: We performed a retrospective chart review documenting patient characteristics and clinical course of SARS-CoV-2 infection between December 2021 and July 2022.
Results: Ten adult patients with IEI followed in our center were diagnosed with COVID-19, as determined by RT-PCR or rapid antigen testing. IEI in this cohort included those with humoral and combined immunodeficiencies, as well as phagocytic defects. An underlying lung comorbidity was identified in 3 patients. Symptoms were mostly mild and self-limiting, and no severe outcomes, complications, or mortality were noted in this study.
Conclusions: We suggest that patients affected by a wide range of both humoral and combined IEI may demonstrate resilience, while highlighting the possible protective effects of vaccination and immunoglobulin replacement in this population.
Statement of Novelty: We report on the mild COVID-19 clinical course of 10 adults with IEI.
Formats available
You can view the full content in the following formats:
REFERENCES
Araf, Y., Akter, F., Tang, Y.-D., Fatemi, R., Parvez, M.S.A., Zheng, C., and Hossain, M.G. 2022. Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines. J. Medical Virol.
Castano-Jaramillo L.M., Yamazaki-Nakashimada M.A., O’Farrill-Romanillos P.M., Muzquiz Zermeño D., Mendoza S.C.S., Montoya E.V., Campos J.A.G., Sánchez-Sánchez L.M., González L.B.G., López J.M.R., Ogando JCB, Vásquez-Echeverri E., Torres E.A.M., Lopez-Herrera G., Galicia L.B., Ruiz L.B., Staines-Boone A.T., Espinosa-Padilla S.E., Mendez N.H.S., and Reyes S.O.L. 2021. COVID-19 in the context of inborn errors of immunity: a case series of 31 patients from Mexico. J. Clin. Immunol. 41: 1463–1478.
Cucinotta D. and Vanelli M. 2020. WHO declares COVID-19 a pandemic. Acta. Biomedica. 91: 157–160.
Esenboga S., Ocak M., Akarsu A., Bildik H.N., Cagdas D., Iskit A.T., and Tezcan I. 2021. COVID-19 in patients with primary immunodeficiency. J. Clin. Immunol. 41, 1515–1522.
Giardino G., Milito C., Lougaris V., Punziano A., Carrabba M., Cinetto F., Scarpa R., Dellepiane R.M., Ricci S., Rivalta B., Conti F., Marzollo A., Firinu D., Cirillo E., Lagnese G., Cancrini C., Martire B., Danieli M.G., Pession A., Vacca A., Azzari C., Fabio G., Soresina A., Agostini C., Spadaro G., Badolato R., Cicalese M.P., Aiuti A., Plebani A., Quinti I., and Pignata C. The impact of SARS-CoV-2 infection in patients with inborn errors of immunity: the experience of the italian primary immunodeficiencies network (IPINet). J. Clin. Immunol. 42(5): 935–946.
Kahn J.S. and Mcintosh K. 2005. History and Recent Advances in Coronavirus Discovery. J. Pediatr. Infect. Dis. 24: S223–S227.
Jin H., Reed J.C., Liu S.T.H., Ho H-E., Lopes J.P., Ramsey N.B., Waqar O., Rahman F., Aberg J.A., Bouvier N.M., and Cunningham-Rundles C., and Mount Sinai Health System Convalescent Plasma Team. 2020. Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. J. Allergy Clin. Immunol. Pract. 8: 3594–3596.e3.
Meyts I.Bucciol G.Quinti I.Neven B.Fischer A.Seoane E.Lopez-Granados E.Gianelli C.Robles-Marhuenda A.Jeandel P-Y.Paillard C.Sankaran V.G.Demirdag Y.Y.Lougaris V.Aiuti A.Plebani A.Milito C.Dalm V.Guevara-Hoyer K.Sánchez-Ramón S.Bezrodnik L.Barzaghi F.Gonzalez-Granado L.I.Hayman G.R.Uzel G.Mendonça L.O.Agostini C.Spadaro G.Badolato R.Soresina AVermeulen F.Bosteels C.Lambrecht B.N.Keller M.Mustillo P.J.Abraham R.S.Gupta S.Ozen A.Karakoc-Aydiner E.Baris S.Freeman A.F.Yamazaki-Nakashimada M.Scheffler-Mendoza S.Espinosa-Padilla S.Gennery A.R.Jolles S.Espinosa Y.Poli M.C.Fieschi C.Hauck F.Cunningham-Rundles C.Mahlaoui N., IUIS Committee of Inborn Errors of ImmunityWarnatz K.Sullivan K.E.Tangye S.G. 2021. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J. Allergy. Clin. Immunol. 147: 520–531.
Shields A.M.Burns S.O.Savic S.RichterUK PIN COVID-19 Consortium. 2021. COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. J. Allergy Clin. Immunol. 147: 870–875.e1.
van Damme K.F.A., Tavernier S., Roy N.V., Leeuw E.D., Declercq J., Bosteels C., Maes B., Bruyne M.D., Bogaert D, Bosteels V., Hoste L., Naesens L., Maes P, Grifoni A., Weiskopf D., Sette A, Depuydt P., Braeckel E.V., Haerynck F, and Lambrecht B.N. 2020. Case report: convalescent plasma, a targeted therapy for patients with cvid and severe COVID-19. Front. Immunol. 11: 596761.
Information & Authors
Information
Published In
LymphoSign Journal
Volume 9 • Number 3 • September 2022
Pages: 62 - 66
History
Received: 10 August 2022
Accepted: 29 August 2022
Accepted manuscript online: 31 August 2022
Copyright
© 2022.
Authors
Metrics & Citations
Metrics
Other Metrics
Citations
Cite As
JennyGarkaby, OriScott, Laura AbregoFuentes, LindaVong, Jessica WillettPachul, MyraPereira, Vy Hong-DiepKim, and Chaim M.Roifman. 2022. Case series of COVID-19 outcomes in adult patients with inborn errors of immunity. LymphoSign Journal.
9(3): 62-66. https://doi.org/10.14785/lymphosign-2022-0009
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
There are no citations for this item
View Options
Get Access
Login options
Check if you access through your login credentials or your institution to get full access on this article.
